| Patent | Date |
|---|
Alcohol Resistant Enteric Pharmaceutical Compositions
App 20180085315 - Liversidge; Gary ; et al. | 2018-03-29 |
Drug Delivery Composition
App 20150283092 - Ruddy; Stephen B. ; et al. | 2015-10-08 |
Injectable Nanoparticulate Olanzapine Formulations
App 20150238505 - Ruddy; Stephen B. ; et al. | 2015-08-27 |
Alcohol Resistant Enteric Pharmaceutical Compositions
App 20140248341 - Liversidge; Gary ; et al. | 2014-09-04 |
Abuse-resistant Pharmaceutical Compositions
App 20140112980 - Vaghefi; Farid ; et al. | 2014-04-24 |
Abuse-resistant pharmaceutical compositions
Grant 8,623,412 - Farid , et al. January 7, 2 | 2014-01-07 |
Injectable Nanoparticulate Olanzapine Formulations
App 20130309310 - Ruddy; Stephen B. ; et al. | 2013-11-21 |
Injectable Nanoparticulate Olanzapine Formulations
App 20120315336 - Ruddy; Stephen B. ; et al. | 2012-12-13 |
In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate or nanoparticulate active agent compositions
Grant 8,309,136 - Cooper , et al. November 13, 2 | 2012-11-13 |
Rapidly Disintegrating Solid Oral Dosage Form
App 20120114754 - Jain; Rajeev A. ; et al. | 2012-05-10 |
Alcohol Resistant Enteric Pharmaceutical Compositions
App 20110223244 - Liversidge; Gary ; et al. | 2011-09-15 |
Nanoparticulate compositions of mitogen-activated protein (MAP) kinase inhibitors
Grant 7,998,507 - Bosch , et al. August 16, 2 | 2011-08-16 |
Nanoparticulate fibrate formulations
Grant 7,931,917 - Ryde , et al. April 26, 2 | 2011-04-26 |
Nanoparticulate fibrate formulations
Grant 7,927,627 - Ryde , et al. April 19, 2 | 2011-04-19 |
Drug Delivery Composition
App 20100260858 - Ruddy; Stephen B. ; et al. | 2010-10-14 |
Controlled-release Clozapine Compositions
App 20100260859 - Ruddy; Stephen B. ; et al. | 2010-10-14 |
In Vitro Methods For Evaluating The In Vivo Effectiveness Of Dosage Forms Of Microparticulate Or Nanoparticulate Active Agent Compositions
App 20100178648 - Cooper; Eugene R. ; et al. | 2010-07-15 |
In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate or nanoparticulate active agent compositions
Grant 7,695,739 - Cooper , et al. April 13, 2 | 2010-04-13 |
Injectable Nanoparticulate Olanzapine Formulations
App 20090155331 - Ruddy; Stephen B. ; et al. | 2009-06-18 |
Rapidly disintegrating solid oral dosage form
App 20090130213 - Jain; Rajeev A. ; et al. | 2009-05-21 |
Fenofibrate Dosage Forms
App 20080241070 - Ryde; Tuula A. ; et al. | 2008-10-02 |
Rapidly disintegrating solid oral dosage form
App 20080213371 - Jain; Rajeev A. ; et al. | 2008-09-04 |
Nanoparticulate fibrate formulations
App 20080138424 - Ryde; Tuula ; et al. | 2008-06-12 |
Nanoparticulate fibrate formulations
App 20080095851 - Ryde; Tuula ; et al. | 2008-04-24 |
Methods of treatment using nanoparticulate fenofibrate compositions
Grant 7,320,802 - Ryde , et al. January 22, 2 | 2008-01-22 |
Nanoparticulate fibrate formulations
App 20070298115 - Ryde; Tuula ; et al. | 2007-12-27 |
Nanoparticulate fibrate formulations
Grant 7,276,249 - Ryde , et al. October 2, 2 | 2007-10-02 |
Sterilized Nanoparticulate Glucocorticosteroid Formulations
App 20070178051 - Pruitt; John ; et al. | 2007-08-02 |
In vitro methods for evaluating the in vivo effectivness of dosage forms of microparticulate or nanoparticulate active agent compositions
App 20070110776 - Cooper; Eugene R. ; et al. | 2007-05-17 |
In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
Grant 7,198,795 - Cooper , et al. April 3, 2 | 2007-04-03 |
Abuse-resistant pharmaceutical compositions
App 20060104909 - Vaghefi; Farid ; et al. | 2006-05-18 |
Nanoparticulate fibrate formulations
App 20050276974 - Ryde, Tuula ; et al. | 2005-12-15 |
Compositions having a combination of immediate release and controlled release characteristics
Grant 6,908,626 - Cooper , et al. June 21, 2 | 2005-06-21 |
Nanoparticulate fibrate formulations
App 20040087656 - Ryde, Tuula ; et al. | 2004-05-06 |
Rapidly disintegrating solid oral dosage form
App 20040057993 - Jain, Rajeev A. ; et al. | 2004-03-25 |
Nanoparticulate fibrate formulations
App 20040058009 - Ryde, Tuula ; et al. | 2004-03-25 |
Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
App 20040029099 - Cooper, Eugene R. ; et al. | 2004-02-12 |
Rapidly disintegrating solid oral dosage form
App 20040013613 - Jain, Rajeev A ; et al. | 2004-01-22 |
Nanoparticulate fibrate formulations
App 20030224058 - Ryde, Tuula ; et al. | 2003-12-04 |
Compositions having a combination of immediate release and controlled release characteristics
App 20030137067 - Cooper, Eugene R. ; et al. | 2003-07-24 |
Nanoparticulate dispersions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
Grant 6,592,903 - Ryde , et al. July 15, 2 | 2003-07-15 |
Formulations for therapeutic agents absorbed through mucous membranes
App 20030054045 - Liversidge, Gary G. ; et al. | 2003-03-20 |
Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
App 20020110597 - Ryde, Niels P. ; et al. | 2002-08-15 |
Methods for targeting drug delivery to the upper and/or lower gastrointestinal tract
Grant 6,432,381 - Liversidge , et al. August 13, 2 | 2002-08-13 |
Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
Grant 6,375,986 - Ryde , et al. April 23, 2 | 2002-04-23 |
Rapidly disintegrating solid oral dosage form
Grant 6,316,029 - Jain , et al. November 13, 2 | 2001-11-13 |
Formulations For Therapeutic Agents Absorbed Through Mucous Membranes
App 20010006617 - LIVERSIDGE, GARY G. ; et al. | 2001-07-05 |
Methods of treating mammals using nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors
Grant 6,221,400 - Liversidge , et al. April 24, 2 | 2001-04-24 |
Methods of making nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
Grant 6,068,858 - Liversidge , et al. May 30, 2 | 2000-05-30 |
Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
Grant 6,045,829 - Liversidge , et al. April 4, 2 | 2000-04-04 |
Nanoparticles containing the R(-)enantiomer of ibuprofen
Grant 5,718,919 - Ruddy , et al. February 17, 1 | 1998-02-17 |
Formulations of oral gastrointestinal diagnostic x-ray contrast agents and oral gastrointestinal therapeutic agents
Grant 5,628,981 - Liversidge , et al. May 13, 1 | 1997-05-13 |
Barium salt formulations stabilized by non-ionic and anionic stabilizers
Grant 5,593,657 - Ruddy , et al. January 14, 1 | 1997-01-14 |
Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays
Grant 5,585,108 - Ruddy , et al. December 17, 1 | 1996-12-17 |
Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
Grant 5,580,579 - Ruddy , et al. December 3, 1 | 1996-12-03 |
Isolation of ultra small particles
Grant 5,503,723 - Ruddy , et al. April 2, 1 | 1996-04-02 |
X-ray contrast compositions containing an organic crystalline X-ray contrast agent in combination with pharmaceutically acceptable clays
Grant 5,360,604 - Ruddy , et al. November 1, 1 | 1994-11-01 |
| 